CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of “Hold” from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) have been given a consensus recommendation of “Hold” by the nineteen research firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $74.59.

CRSP has been the subject of several analyst reports. Robert W. Baird started coverage on shares of CRISPR Therapeutics in a research note on Monday, March 6th. They issued a “neutral” rating and a $46.00 target price for the company. Citigroup decreased their target price on CRISPR Therapeutics from $63.00 to $55.00 in a report on Friday. Morgan Stanley upped their price target on CRISPR Therapeutics from $37.00 to $39.00 and gave the stock an “underweight” rating in a report on Monday, February 27th. Needham & Company LLC decreased their price target on CRISPR Therapeutics from $122.00 to $82.00 and set a “buy” rating for the company in a report on Wednesday, February 22nd. Finally, JMP Securities restated a “market outperform” rating and issued a $70.00 price target on shares of CRISPR Therapeutics in a report on Monday, February 27th.

CRISPR Therapeutics Trading Up 0.8 %

Shares of CRSP opened at $45.74 on Friday. The firm has a market cap of $3.60 billion, a PE ratio of -5.46 and a beta of 1.73. The company’s 50 day simple moving average is $49.78 and its 200-day simple moving average is $53.71. CRISPR Therapeutics has a 12-month low of $38.94 and a 12-month high of $86.95.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last posted its quarterly earnings data on Tuesday, February 21st. The company reported ($1.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.27) by $0.86. CRISPR Therapeutics had a negative net margin of 54,271.70% and a negative return on equity of 31.85%. The firm had revenue of $6.00 million for the quarter, compared to analyst estimates of $7.37 million. During the same period last year, the firm posted ($1.84) EPS. CRISPR Therapeutics’s quarterly revenue was down 53.5% on a year-over-year basis. As a group, equities research analysts forecast that CRISPR Therapeutics will post -7.54 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction dated Friday, January 27th. The stock was sold at an average price of $51.47, for a total value of $1,286,750.00. Following the completion of the sale, the chief executive officer now directly owns 369,111 shares of the company’s stock, valued at approximately $18,998,143.17. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 75,000 shares of company stock valued at $3,516,250. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its holdings in shares of CRISPR Therapeutics by 2,440.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 381 shares of the company’s stock valued at $25,000 after acquiring an additional 366 shares during the last quarter. Hollencrest Capital Management acquired a new position in shares of CRISPR Therapeutics during the 4th quarter valued at about $25,000. Whittier Trust Co. increased its holdings in shares of CRISPR Therapeutics by 224.0% during the 4th quarter. Whittier Trust Co. now owns 674 shares of the company’s stock valued at $27,000 after acquiring an additional 466 shares during the last quarter. HM Payson & Co. grew its holdings in CRISPR Therapeutics by 500.0% in the 3rd quarter. HM Payson & Co. now owns 480 shares of the company’s stock valued at $31,000 after buying an additional 400 shares during the last quarter. Finally, Country Trust Bank acquired a new stake in CRISPR Therapeutics in the 3rd quarter valued at approximately $33,000. 71.51% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.